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Abstract Purpose: Selective
decontamination of the digestive tract
(SDD) has been shown to decrease
the infection rate and mortality in
intensive care units (ICUs); Lactoba-
cillus plantarum 299/299v plus ﬁbre
(LAB) has been used for infection
prevention and does not harbour the
potential disadvantages of antibiotics.
The objective was to assess whether
LAB is not inferior to SDD in infec-
tion prevention. Methods: Two
hundred ﬁfty-four consecutive ICU
patients with expected mechanical
ventilation C48 h and/or expected
ICU stay C72 h were assigned to
receive SDD: four times daily an oral
paste (polymyxin E, gentamicin,
amphotericin B), enteral solution
(same antibiotics), intravenous cefo-
taxime (ﬁrst 4 days) or LAB: two
times daily L. plantarum 299/299v
with rose-hip. Results: The primary
endpoint was infection rate. A dif-
ference\12% between both groups
indicated non-inferiority of LAB. The
trial was prematurely stopped after a
study reporting increased mortality in
critically ill pancreatitis patients
receiving probiotics. No signiﬁcant
difference in infection rate [31% in
the LAB group, 24% in the SDD
group (OR 1.68, 95% CI 0.91–3.08;
p = 0.10)] was found. ICU mortality
was 26% and not signiﬁcantly dif-
ferent between the LAB and SDD
groups. Gram-positive cocci and
Pseudomonas aeruginosa were sig-
niﬁcantly more frequently isolated
from surveillance cultures in the SDD
group compared to the LAB group
(for sputum: 18 vs. 10% and 33 vs.
14%). Signiﬁcantly more Enterobac-
teriaceae were found in the LAB
group (23 vs. 50%). No increase in
antibiotic resistance was found during
and after SDD or LAB use. Conclu-
sions: The trial could not
demonstrate the non-inferiority of
LAB compared with SDD in infection
prevention. Results suggest no
increased ICU mortality risk in the
LAB group.
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Intensive care unit (ICU)-acquired infections have been
estimated to occur in at least 17% of patients [1] and are
associated with increased ICU stay, mortality and health
care costs [2]. Most of these infections are thought to be
precededbyoropharyngealandintestinalcolonisationwith
potentially pathogenic microorganisms [3]. Selective
decontamination of the digestive tract (SDD) and oro-
pharynx (SOD), used in the ICU [4], aim at the elimination
of potentially pathogenic microorganisms from the oro-
pharyngeal cavity, stomach and gut, while leaving the
anaerobic ﬂora intact. Since the introduction of SDD,
randomised clinical trials and meta-analyses have shown a
decrease in mortality [5–8]. However, SDD has been
associated with the emergence of antibiotic-resistant
microorganisms during and after intervention [9].
A method with the beneﬁcial effects of SDD, but
without the risk of selection of antibiotic-resistant
microorganisms would be ideal.
After ingestion, lactic acid bacteria and fermentable
ﬁbre enhance intestinal barrier function, and compete
with pathogens for adhesion and nutrients to create an
unfavourable local milieu for pathogen colonisation [10,
11]. Use of Lactobacillus plantarum 299/299v and ﬁbre
(LAB) decreased hospital-acquired infections in patients
that had abdominal surgery and acute pancreatitis com-
pared with placebo [12, 13]. In liver transplant patients,
these lactobacilli were superior to SDD in the prevention
of nosocomial infections [14]. The aim of the study was to
investigate whether treatment with Lactobacillus planta-
rum 299/299v and rose-hip is non-inferior to SDD in
preventing infection in a general ICU population.
Materials and methods
Setting and participants
Consecutive patients admitted to the ICU at the Maas-
tricht University Medical Centre (MUMC, 705 beds) and
the Atrium Medical Centre Heerlen (a 545-bed teaching
hospital) were enrolled from June 2005 to January 2008
and September 2006 to January 2008. The participating
ICUs are similar in patient population, severity of disease
(mean APACHE II scores are comparable) and mortality
rates (data not shown).
Eligibility criteriawere as appliedbefore[5].However,
amphotericinBsuspensionandlactobacilliplusrose-hipdo
not pass through nasoduodenal tubes. Therefore, use of
these tubes was added as an exclusion criterion, in addition
to contraindications for enteral feeding.
The study protocol was approved by the institutional
review boards for human studies of both participating
centres. Procedures followed were in accordance with the
Helsinki Declaration of 1964. Written informed consent
was obtained from patients or their legal representatives
before enrolment in the trial. The trial has been registered
in the Dutch Trial Register (http://www.trialregister.nl/
trialreg/index.asp), no. NTR1411.
Allocation and interventions
In the MUMC, the study had an open label, crossover of
units design. The Intensive Care department consists of
two separate units (9 and 8 beds) with different case mix
and disease burden. To prevent cross-colonisation, ran-
domisation on a patient level was not possible, and
allocation on a unit level was instituted. Crossover of
units was necessary to correct for possible differences in
case mix, disease burden and other possible confounders.
Patients were allocated to a unit by medical staff not
involved in the study. In case more than one bed was
available in the ICU, patients were randomly assigned to a
unit. The ﬁrst inclusion period lasted 18 months, followed
by a wash-out period of 3 months. Due to results of the
PROPATRIA trial, in which increased mortality in criti-
cally ill patients with severe pancreatitis receiving
probiotics was shown [15], the second inclusion period
was prematurely stopped after 11 months.
In the Atrium MC, one ICU (6 beds) participated in
the study. A 10-month intervention period of LAB was
followed by a 3-month wash-out period and a prematurely
stopped 4-month intervention period of SDD.
Selective decontamination of the digestive tract
patients received a regimen as previously described [5],
except that gentamicin was applied instead of tobramycin.
Topical study medication was manufactured and the
quality tested by the pharmacy of the MUMC.
LAB patients received a solution of viable Lactoba-
cillus plantarum 299/299v in a dose of 5 9 10
9 colony-
forming units (cfu) together with 6 g of rose-hip (Probi
AB, Lund, Sweden). The manufactured freeze-dried
powder was dissolved in 75 ml of water and applied two
times daily through a nasogastric tube.
In case of gastric retention, deﬁned as [1,000 ml/
24 h, either tube feeding was administered through a
nasoduodenal tube or a prokinetic agent was prescribed at
the physician’s discretion. Administration of study prod-
uct was continued by nasogastric tube until ICU
discharge, death or ﬁnal removal of the tube. Therapeutic
use of antibiotics was left to the attending physician’s
discretion, whereas administration of prophylaxis was
continued without dose adjustments.
Outcomes and follow-up
Infections were retrospectively determined using the
Centres for Disease Control and Prevention (CDC)
111criteria [16] and modiﬁed CDC criteria [17] in case of
clinical suspicion of a ventilator-associated pneumonia
(VAP). Urinary tract infections (UTIs) were only
assigned when other infections could be ruled out.
Events occurring [48 h after ICU admission were con-
sidered ICU-acquired. When a VAP was clinically
suspected, bronchoalveolar lavage (BAL) was performed
to the attending intensivist’s discretion, and antibiotic
therapy was started or adjusted empirically. Conﬁrma-
tion of clinically suspected VAP required C2% cells
containing intracellular organisms and/or a quantitative
culture result of C10
4 cfu/ml in BAL ﬂuid [16, 17]. Two
researchers (G.J.O. and A.V.) determined whether
patients met the criteria of infection using predeﬁned
criteria, independently from one another and unaware of
the study regimen. Necessary data were coded without
information about the study arm. Whenever no consen-
sus was reached, a third author (D.C.B.) reviewed the
data.
In ICU, surveillance cultures of sputum and urine
were taken twice weekly. A rectal swab was taken prior
to ﬁrst administration of either study product. Thereafter,
swabs were taken weekly until death or a maximum of
2 weeks after ICU discharge. E. coli and enterococci
were isolated from the swabs as indicator organisms.
CLSI breakpoints for antibiotic resistance were applied
[18]. Data on antibiotic consumption, other than SDD
agents, were recorded using the anatomical therapeutic
chemical (ATC) classiﬁcation system and were expressed
as deﬁned daily doses (DDD) per 100 patient days [19,
20].
Medical ﬁles of patients who died during ICU stay
were retrospectively screened for signs and symptoms of
small bowel ischemia.
The primary endpoint was infection during ICU stay.
Assuming that SDD use results in an estimated infection
prevalence of 25% [21], a difference larger than half of
this percentage (i.e., 12%) had to be excluded to
hypothesise an equivalent efﬁcacy of LAB compared with
SDD (non-inferiority). One hundred eighty-ﬁve patients
had to be enrolled in each group, based on a = 0.05 (one-
sided) and a power of 80%.
Early onset infections were deﬁned as infections
occurring within 48–96 h after ICU admission. Infection
at ICU admission was deﬁned as a combination of clinical
diagnosis of infection by the attending intensivist and
antibiotic use at admission.
Secondary endpoints were ICU mortality and in-hos-
pital mortality. In-hospital mortality was not regarded as a
proper endpoint within this open label study design [7, 22,
23] and was retrospectively discarded. Mortality at day 28
was added.
Other secondary endpoints were additional use of
systemic antibiotics and prevalence of (antibiotic-resis-
tant) microorganisms in surveillance cultures.
Statistical analysis
To compare speciﬁc variables, the Pearson v
2 and Mann-
Whitney U test were used. A two-way contingency table
analysis was performed to calculate differences in pro-
portions, regarding patients with infectious events, and
the respective 95% conﬁdence intervals (CI). Logistic
regression models, regarding mortality and proportion of
patients with infections, were used to adjust for differ-
ences in prognostic variables and severity of disease,
using the APACHE II score [7, 24], age [7], sex [7], BMI
[25] and ICU as covariates.
For time-to-infectious event analysis, a Kaplan-Meier
curve with log rank test was generated. Analysis was done
with SPSS 15.0 for Windows (SPSS Benelux BV, Gor-
inchem, The Netherlands). A Poisson analysis, with the
number of infections per patient as dependent variable,
and the intervention and the above-mentioned covariates
as independent variables, was performed using STATA
10.0 (STATA Corporation, College Station, TX). All
analyses were based on the intention-to-treat principle.
No interim analysis was performed because of the cross-
over design. Statistical signiﬁcance was deﬁned as a
p value of less than 0.05 in all cases.
Results
Patient population
Enrolment involved 254 consecutive ICU patients (i.e.,
73% of eligible patients, Fig. 1), 222 in the MUMC and
32 in the Atrium MC. Inclusion rates were similar in both
hospitals. Both study groups were comparable for all
baseline and follow-up characteristics (Table 1), as were
patients in the two participating centres (data not shown).
The prevalence of infection at admission was 39% in the
SDD group and 32% in the LAB group (p = 0.29).
348 eligible patients 
174 assigned to 
SDD unit 
174 assigned to 
LAB unit 
25 unable to 
ask consent 
19 refused 
to participate
130 patients 
included in 
LAB group 
19 unable to 
ask consent 
31 refused 
to participate 
124 patients 
included in 
SDD group 
Fig. 1 Flowchart of patient enrolment. SDD selective decontam-
ination of the digestive tract, LAB, L. plantarum 299/299v plus ﬁbre
112ICU-acquired infections
The acquired infection rate was 28% (70/254); 40 of 130
patients given LAB (31%) and 30 of 124 patients
receiving SDD (24%, Table 2). Adjusted for BMI, age,
sex, APACHE II score and ICU, the difference between
both groups was not statistically signiﬁcant [odds ratio
(OR) 1.68, 95% CI 0.91–3.08; p = 0.10]. The time to
infection was similar in both study groups (p = 0.38,
Fig. 2). When UTIs were excluded from the analysis,
differences remained non-signiﬁcant (OR 1.23, 95% CI
0.63–2.40; p = 0.54 for infections and p = 0.90 for time
to infection). The total number of infections was not
signiﬁcantly different (p = 0.25, Table 2), nor was the
number of infections per patient with (p = 0.35, Table 2)
or without UTIs (p = 0.43, data not shown). In the SDD
group, nine episodes of VAP occurred during 1,674 days
of mechanical ventilation (MV, 5.4 VAPs/1,000 days). In
the LAB group, ten episodes of VAP occurred during
2,156 days of MV (4.6 VAPs/1,000 days, N.S.). Four out
Table 1 Characteristics of the study population
Characteristic LAB
group
(n = 130)
SDD
group
(n = 124)
p Value
Sex
Male (%) 84 (65) 73 (59) 0.35
Age in years
Mean (SD) 63.5 (16.4) 61.9 (16.0) 0.26
Range 20–90 17–90
BMI in kg/m
2
Mean (SD) 25.5 (4.9) 25.4 (4.5) 0.98
Range 17.3–55.9 16.6–47.8
APACHE II score
Mean (SD) 23 (7.7) 21 (7.6) 0.11
Range 7–44 7–40
Days in hospital
Mean (SD) 36.7 (33.9) 38.5 (33.5) 0.35
Range 2–193 1–227
Days in ICU
Mean (SD) 18.0 (24.8) 15.0 (17.8) 0.78
Range 1–155 1–105
Reason for ICU admission (%)
Respiratory insufﬁciency 46 (35.4) 39 (31.5)
Neurological 31 (23.8) 36 (29.0)
Hemodynamic 13 (10.0) 9 (7.3) 0.68
Sepsis/shock 17 (13.1) 21 (16.9)
Peritonitis 9 (6.9) 5 (4.0)
Trauma/other
a 14 (10.8) 14 (11.3)
Admission group (%)
Surgical 64 (49.2) 69 (55.6)
Medical 62 (47.7) 50 (40.3) 0.49
Trauma 4 (3.1) 5 (4.0)
Patients on MV (%) 129 (99.2) 119 (96.0) 0.09
Days on MV
Mean (SD) 16.7 (23.6) 14.1 (17.2) 0.60
Range 2–152 1–100
Number of days with administration of study product
b
Mean (SD) 11.0 (14.3) 10.5 (13.8) 0.87
Range 0–73 0–94.25
Cumulative gastric retention in milliliters
Mean (SD) 3,002 (6,368) 2,264 (3,713) 0.74
Range 0–53,670 0–23,885
LAB L. plantarum 299/299v plus ﬁbre; SDD selective decontam-
ination of the digestive tract; BMI body mass index; APACHE
acute physiology and chronic health evaluation; ICU intensive care
unit; MV mechanical ventilation
a Including acidosis, bowel ischemia, meningitis, renal insufﬁ-
ciency, weaning problems, Guillain-Barre ´ syndrome,
retroperitoneal haematoma, pancreatitis, encephalopathy, necro-
tising fasciı ¨tis, pelvic exenteration, traumatic spinal cord injury
b In LAB group two times daily, in SDD group four times daily
Table 2 Number and type of infectious events
Type of infection LAB group
(n = 130)
SDD group
(n = 124)
Total events (%)* 67 (100) 42 (100)
Ventilator-associated pneumonia (%) 10 (14.9) 9 (21.4)
Pneumonia
a (%) 2 (3.0) –
Urinary tract infection (%) 30 (44.8) 8 (19.0)
(Catheter-related) bloodstream
infection (%)
16 (23.9) 16 (38.1)
Wound infection (%) 2 (3.0) 3 (7.1)
Intra-abdominal infection (%) 4 (6.0) 3 (7.1)
Other
b (%) 3 (4.5) 3 (7.1)
Number of infections**
Patients with 0 infections (%) 90 (69.2) 94 (75.8)
Patients with 1 infection (%) 23 (17.7) 20 (16.1)
Patients with 2 infections (%) 12 (9.2) 9 (7.3)
Patients with C3 infections (%) 5 (3.8) 1 (0.8)
LAB L. plantarum 299/299v plus ﬁbre; SDD selective decontami-
nation of the digestive tract
* p = 0.25
** p = 0.35
a Involved patients were not mechanically ventilated
b Including (pulmonary) abcess, sinusitis, empyema
time until first infection (days)
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Fig. 2 Kaplan-Meier time-to-event analysis for the incidence of
infectious events. p = 0.38, by log rank test. SDD, selective
decontamination of the digestive tract; LAB, L. plantarum 299/
299v plus ﬁbre
113of 30 infectious events in the SDD group were early
onset (13.3%) versus 7/40 in the LAB group (17.5%,
p = 0.64). The difference in infection rate between both
study groups was 7% (95% CI -4.4 to 17.1%) in the 254
included patients. When extrapolated to the calculated
necessary sample size of 370 patients, the 95% CI ranged
from -2.6 to 15.3%. With UTIs excluded, the difference
in infection rate was 2% (95% CIs -8.3 to 10.9% and -7
to 9.1%, respectively).
The absolute number of Gram-positive cocci and
P. aeruginosa causing infections was comparable
between both groups. However, proportionally, signiﬁ-
cant differences in prevalence were present (Table 3).
Between both groups, no signiﬁcant differences in anti-
biotic resistance of microorganisms of the same species
were found during the study period for any antibiotic.
Moreover, resistance levels did not increase over time.
Mortality
Overall ICU mortality was 26%. ICU mortality, adjusted
for the above-mentioned confounders, was not signiﬁ-
cantly different between SDD and LAB (OR 0.99, 95%
CI 0.51–1.92; p = 0.97), nor was adjusted mortality at
day 28 (OR 1.31, 95% CI 0.68–2.53; p = 0.43). Mor-
tality rates were similar for both participating centres. No
patients receiving LAB or SDD developed bowel ische-
mia as considered by autopsy and/or chart review.
Additional antibiotic use
The total mean number of DDD/100 patient days was
signiﬁcantly higher in the LAB group than in the SDD
group (141.7 vs. 108.7, p = 0.008, Table 4). This could
be explained by the signiﬁcantly higher use of co-amox-
iclav in the LAB group (p = 0.003, Table 4). During the
ﬁrst 72 h after ICU admission, 103 SDD patients and 108
LAB patients used a total of 368 DDD and 411 DDD,
with a mean of 3.6 and 3.8 DDD/patient (N.S.),
respectively.
Surveillance cultures
In 64 patients, 277 isolates were cultured from 215
positive sputum samples in the SDD group and 516/326
from 73 patients in the LAB group (p\0.001). Signiﬁ-
cantly more Gram-positive cocci (50/277 isolates vs.
52/516, 25 vs. 23 patients) and Pseudomonas aeruginosa
(92/277 vs. 70/516, 18 vs. 14 patients) were cultured in
the SDD group (p = 0.001 and p\0.001, respectively),
whereas more Enterobacteriaceae (63/277 vs. 259/516,
24 vs. 57 patients) and Acinetobacter species (1/277 vs.
23/516, 1 vs. 4 patients) were found in the LAB group
(p\0.001 and p = 0.001, respectively).
In 22 patients, 57 isolates were cultured from 54
positive urine samples in the SDD group and 136/111
from 42 patients in the LAB group (p\0.001). The
prevalence of enterococci (10/57 isolates vs. 12/136, 8
vs. 7 patients) and P. aeruginosa (14/57 vs. 10/136, 6 vs.
6 patients) was higher in the SDD group (p = 0.08 and
p = 0.001, respectively), and of Enterobacteriaceae (for
E. coli 7/57 vs. 38/136, 4 vs. 18 patients) in the LAB
group (p = 0.02).
The prevalence of enterococci in rectal swabs (not
different at t = 0) signiﬁcantly increased over time
Table 3 Microorganisms that caused infectious events
LAB group SDD group
Total number of microorganisms (%) 97 (100) 51 (100)
Gram-positive
Enterococcus species (%) 10 (10) 11 (22)*
Coagulase-negative staphylococci (%) 7 (7) 10 (20)*
Staphylococcus aureus (%) 6 (6) 3 (6)
Other (%) 4 (4) 2 (4)
Gram-negative
Pseudomonas aeruginosa (%) 10 (10) 12 (24)*
Enterobacteriaceae (%) 44 (45)* 9 (18)
Other (%) 7 (7) 1 (2)
Candida species (%) 9 (9) 3 (6)
* p\0.05
LAB L. plantarum 299/299v plus ﬁbre; SDD selective decontami-
nation of the digestive tract
Table 4 Additional antibiotic use in both study groups in mean
DDD/100 patient days
Antibiotic SDD group LAB group
Amoxicillin 4.8 5.7
Piperacillin 2.5 0.9
Flucloxacillin 8.4 15.3
Co-amoxiclav 34.7 49.3**
Piperacillin–tazobactam 9.4 12.8
Cefazoline 2.1 0.5
Cefuroxime 0.8 –
Ceftazidime 2.9 0.7
Ceftriaxone 0.5 7.7**
Carbapenems 2.7 0.9
Co-trimoxazol 1.2 3.0
Macrolides
a/clindamycin 5 2.9
Gentamicin 3.4 8.5
Fluoroquinolones 15.5 22.0
Vancomycin 4.6* 1.1
Other
b 10.2 10.4
Total 108.7 141.7**
Antibiotics for systemic administration, unless stated otherwise.
DDD deﬁned daily dose; SDD selective decontamination of the
digestive tract; LAB L. plantarum 299/299v plus ﬁbre
* p\0.05, by Mann-Whitney U test
** p\0.01, by Mann-Whitney U test
a Clarithromycin was administered orally
b Including benzylpenicillin, aztreonam, metronidazol, rifampicin
and colistin
114during prophylaxis with both SDD and LAB, to a
respective maximum of 96 and 88% (N.S.). After cessa-
tion of prophylaxis, this increased percentage persisted.
The prevalence of E. coli (not different at t = 0) dimin-
ished over time during prophylaxis to 0 and 24%,
respectively (p\0.001). After cessation of prophylaxis,
the prevalence tended to increase (N.S.).
Antibiotic resistance among Enterobacteriaceae, non-
fermenting species other than Pseudomonas, Candida
species, staphylococci and enterococci in sputum and
urine samples did not differ signiﬁcantly between both
study groups at any time point throughout the entire study
period (data not shown). Among P. aeruginosa isolates,
resistance to ceftazidime (p = 0.02), ciproﬂoxacine
(p\0.001), piperacillin (p = 0.004) and piperacillin-ta-
zobactam (p = 0.02) was signiﬁcantly higher in the LAB
group than in the SDD group. Prevalence of resistance in
both groups did not increase signiﬁcantly over time. No
putative ESBL producers were found among Klebsiella
pneumoniae isolates.
Discussion
This trial failed to demonstrate non-inferiority of the
probiotic L. plantarum 299/299v plus rose-hip (LAB)
compared with SDD in prevention of ICU-acquired
infections. Rather, the results suggest that LAB might be
inferior to SDD. The difference in ICU mortality and
mortality at day 28 was not statistically signiﬁcant
between both groups. No signiﬁcant difference in preva-
lence of antibiotic-resistant bacteria was recorded
between clinical isolates of 130 patients receiving LAB
and 124 patients receiving SDD.
Infection rates in ICU studies have been shown to vary
from 28 to 90% when no infection prevention regimen is
used [12, 15, 26, 27]. Infection rates using probiotics for
prevention varied from 10 to 30% [12, 14, 15]. Using
LAB, an infection rate of 31% was found in our study. A
large proportion of these infections was due to UTIs
(Table 2), which seemed to be prevented by SDD.
Exclusion of UTIs resulted in a rate of 21% in the LAB
group. The higher additional antibiotic use in the LAB
group, in particular co-amoxiclav, may have masked or
prevented infectious complications.
The infection rates with SDD in our study were lower
than those previously reported (34–43%) [6, 28]. The
proportional differences in prevalence of microorganisms
(of infectious events as well as surveillance cultures)
between both study groups were as expected, since SDD
mainly eliminates Enterobacteriaceae [29]. Resistance
levels among bacteria causing infections were comparable
to those described in Dutch ICUs [30].
The overall mortality rate of 26% in the present study
was within the range described by Knaus et al. [24] for (a
group of) patients with a (mean) APACHE II score of 22.
The ICU mortality in the LAB group was not signiﬁcantly
different from that in the SDD group. SDD has already
been proven to reduce mortality compared with placebo
or standard care [5–8].
Effects of probiotics on mortality depend on the kind
of probiotics used [26, 27]. Our study was not powered to
detect a difference in mortality, and inclusion was pre-
maturely stopped. Therefore, no beneﬁt of SDD versus
LAB on mortality could be evaluated. Our data do suggest
that not all probiotics administered to critically ill patients
result in an increased risk of mortality.
The increased mortality risk in patients with severe
pancreatitis and probiotic prophylaxis (16%) compared
with placebo (6%) [15] could not be conﬁrmed by our
trial, which had a similar sample size. There are several
differences between our study and the PROPATRIA trial.
Firstly, the study populations were different. Secondly,
the probiotic L. plantarum 299/299v differed from the
PROPATRIA trial probiotic mixture (six different strains)
[15], and the antimicrobial and immunological properties
of the different probiotic strains vary greatly [31, 32].
Thirdly, patients in the present study received probiotics
via nasogastric tubes. In the PROPATRIA trial, nasojej-
unal tubes were used [15]. Small bowel feeding has been
shown to be associated with ischemic bowel disease in
patients started on early enteral feeding after an abdom-
inal procedure [33].
One limitation of the present study is the premature
ending, which prevented the completion of patient
enrolment. Crossover of units was deemed necessary after
allocation on a unit level to prevent cross-colonisation
[34, 35]. However, the crossover of units was not com-
pleted, resulting in an unequal mix of patients and disease
burden, so the adjustments in the analyses, as mentioned
above, had to be made. Another limitation could be that
the study was not double-blinded, because surveillance
cultures reveal on which unit SDD was used and on which
unit not. Masking of these cultures would be impossible
and unethical since additional antibiotic treatment has to
be based on these culture results. Furthermore, one unit
was designated the SDD unit and the other the LAB unit
to prevent cross-colonisation between SDD and LAB
patients. The fact that infections were deﬁned retrospec-
tively may have been a limitation, despite the fact that the
examiners were blinded for the preventive treatment
assigned to the patients.
A fourth limitation could be that only E. coli and
enterococci were isolated from rectal swabs, whereas no
oropharyngeal cultures were taken, thereby hampering the
classiﬁcation of infections in endogenous and exogenous.
Thus, a concomitant exogenous problem affecting both
study groups and causing infections cannot be ruled out.
In conclusion, the 130 critically ill patients receiving
probiotics did not show a signiﬁcantly increased ICU
mortality or mortality at day 28 compared with the 124
115patients receiving SDD. On the other hand, there was a
tendency towards more infections in patients receiving
LAB compared with SDD.
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